Use of nalmefene in patients with comorbid borderline personality disorder and alcohol use disorder
Authors:
- Barbara PatriziBPBarbara Patrizi
- Joaquim SolerJSJoaquim Soler
- Xero GasolXGXero Gasol
- Matilde ElicesMEMatilde Elices
- Miquel GasolMGMiquel Gasol
- Cristina CarmonaCCCristina Carmona
- Juan C. PascualJPJuan C. Pascual
- 1 July 2017
- journal article
- clinical trial
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 32 (4) , 231-234
Abstract
Comorbidity between borderline personality disorder (BPD) and alcohol use disorder (AUD) is high and relevant as alcohol consumption seems to worsen BPD symptomatology. One of the newest treatments for AUD, nalmefene, may be useful to improve BPD symptoms not only indirectly by reducing alcohol consumption but also directly by acting on the opioid system as this system has been related to specific BPD symptoms. This open-label study aimed at evaluating the efficacy of an 8-week nalmefene treatment in reducing alcohol consumption in individuals with BPD and comorbid AUD. A secondary objective was to assess its efficacy in improving general BPD symptomatology and specific behaviors (self injury and binge eating). Eighteen out of the 25 patients with BPD and comorbid AUD enrolled in the study completed all the assessment points. After 8 weeks, a significant reduction was observed in alcohol consumption, BPD global symptomatology, self-injurious behavior, and binge eating. No serious adverse effects were reported; however, five participants experienced mild side effects, resulting in withdrawal from the study in two cases. According to our results, nalmefene may be a safe and effective drug for treating patients with BPD and comorbid AUD. Controlled clinical trials are needed to support our findings.Keywords
This publication has 14 references indexed in Scilit:
- Comorbidity of Borderline Personality Disorder and Lifetime Substance Use Disorders in a Nationally Representative SampleJournal of Personality Disorders, 2016
- The overlap between binge eating disorder and substance use disorders: Diagnosis and neurobiologyJournal of Behavioral Addictions, 2013
- A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependenceEuropean Neuropsychopharmacology, 2013
- Validation of the Spanish version of the borderline symptom list, short form (BSL-23)BMC Psychiatry, 2013
- Extending the Treatment Options in Alcohol Dependence: A Randomized Controlled Study of As-Needed NalmefeneBiological Psychiatry, 2013
- Opioid modulators for alcohol dependenceExpert Opinion on Investigational Drugs, 2011
- The Short Version of the Borderline Symptom List (BSL-23): Development and Initial Data on Psychometric PropertiesPsychopathology, 2008
- Prevalence, Correlates, Disability, and Comorbidity of DSM-IV Borderline Personality DisorderThe Journal of Clinical Psychiatry, 2008
- Borderline Personality Disorder and Substance Abuse: Consequences of ComorbidityThe Canadian Journal of Psychiatry, 1995
- The Diagnosis of Personality Disorder With a Modified Version of the SCID-II in A Spanish Clinical SampleJournal of Personality Disorders, 1994